Biota Pharmaceuticals Inc. (AVIR) Earns “Buy” Rating from FBR & Co

FBR & Co reiterated their buy rating on shares of Biota Pharmaceuticals Inc. (NASDAQ:AVIR) in a report published on Monday.

Other equities analysts have also recently issued reports about the company. Ladenburg Thalmann started coverage on Biota Pharmaceuticals in a report on Wednesday, September 21st. They issued a buy rating on the stock. HC Wainwright reiterated a buy rating on shares of Biota Pharmaceuticals in a report on Tuesday, September 20th. Five equities research analysts have rated the stock with a buy rating, Biota Pharmaceuticals presently has an average rating of Buy and an average target price of $5.50.

Biota Pharmaceuticals (NASDAQ:AVIR) traded down 0.368% during trading on Monday, hitting $1.355. 13,719 shares of the company traded hands. Biota Pharmaceuticals has a 12-month low of $1.15 and a 12-month high of $2.28. The stock has a 50 day moving average price of $1.55 and a 200 day moving average price of $1.47. The company’s market capitalization is $52.36 million.

A number of institutional investors have recently modified their holdings of AVIR. California Public Employees Retirement System bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $139,000. BlackRock Fund Advisors bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $143,000. Towerview LLC bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $224,000. Dimensional Fund Advisors LP bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $290,000. Finally, BVF Inc. IL bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at $292,000. Institutional investors and hedge funds own 34.52% of the company’s stock.

Biota Pharmaceuticals Company Profile

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.